Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442814 | 1.00 | GAA (0.40) | GAATP53UBE2NSMN1; SMN2CYP3A4 | |
| SCHEMBL443194 | 0.79 | GAA (0.37) | GAATP53UBE2NSMN1; SMN2CYP3A4 | |
| SCHEMBL443195 | 0.79 | GAA (0.37) | GAATP53UBE2NSMN1; SMN2CYP3A4 | |
| SCHEMBL441675 | 0.78 | GAA (0.44) | GAATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL463005 | 0.78 | TP53 (0.42) | GAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2588381 | 0.78 | TP53 (0.42) | GAATP53SMN1; SMN2 | |
| SCHEMBL2588378 | 0.78 | TP53 (0.42) | GAATP53SMN1; SMN2 | |
| SCHEMBL438897 | 0.78 | ALDH1A1 (0.37) | GAATP53UBE2NSMN1; SMN2ALDH1A1 | |
| SCHEMBL438898 | 0.78 | ALDH1A1 (0.37) | GAATP53UBE2NSMN1; SMN2ALDH1A1 | |
| SCHEMBL29988105 | 0.75 | ALDH1A1 (0.59) | GAASMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | GAA 106/4885TP53 2780/4885UBE2N 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.